(Total Views: 939)
Posted On: 01/03/2022 11:50:12 PM
Post# of 148903
Re: Goosebumps #113691
"The article didn’t slam Leronlimab really in my view it was more directed at the clinics lack of success."
While the article, by it's title, seems to be concerned with Long-haulers, it is more of an exposure of InCellDX, the lack of science, Dr Patterson and Dr Yo's sleaziness. The little bit about Leronlimab, and Cytodyn, was a bit of a shot (in my opinion). It implies there was no efficacy in the drug, Covid-19, via the FDA hit letter. The author felt it necessary to point out that Cytodyn was making false claims about Leronlimab's safety and efficacy. Yet, the author didn't feel that it was either necessary to point out that Leronlimab did show efficacy or that Cytodyn did run a successful trial for treatment of Long-hauler's symptoms. Furthermore, the author failed to point out that Cytodyn will run another Long-hauler's trial, as soon as the FDA approves the protocols. I'm with Ken on this one. If you're going to drag someone else into your article, do a little research and complete the story. Therefore, I disagree with your take, that it wasn't a hit on Leronlimab. It is just another half-assed, poorly written article which showed that the author doesn't give a damn about what they write.
Read More: https://investorshangout.com/post/view?id=631...z7GyNikSkB
While the article, by it's title, seems to be concerned with Long-haulers, it is more of an exposure of InCellDX, the lack of science, Dr Patterson and Dr Yo's sleaziness. The little bit about Leronlimab, and Cytodyn, was a bit of a shot (in my opinion). It implies there was no efficacy in the drug, Covid-19, via the FDA hit letter. The author felt it necessary to point out that Cytodyn was making false claims about Leronlimab's safety and efficacy. Yet, the author didn't feel that it was either necessary to point out that Leronlimab did show efficacy or that Cytodyn did run a successful trial for treatment of Long-hauler's symptoms. Furthermore, the author failed to point out that Cytodyn will run another Long-hauler's trial, as soon as the FDA approves the protocols. I'm with Ken on this one. If you're going to drag someone else into your article, do a little research and complete the story. Therefore, I disagree with your take, that it wasn't a hit on Leronlimab. It is just another half-assed, poorly written article which showed that the author doesn't give a damn about what they write.
Read More: https://investorshangout.com/post/view?id=631...z7GyNikSkB
(7)
(0)Scroll down for more posts ▼
